You are here: Industry Insights > Calquence

News List

AztraZeneca to launch oncology drug Calquence in India expresspharma
October 19, 2020
AstraZeneca Pharma India has received import and market permission in Form CT-20 (Marketing Authorization- Additional Indication) from the Drugs Controller General of India for Acalabrutinib 100 mg capsules (Calquence ).
Calquence Recommended for CHMP Approval for Chronic Lymphocytic Leukemia americanpharmaceuticalreview
July 31, 2020
AstraZeneca’s Calquence (acalabrutinib) has been recommended for marketing authorization in the European Union (EU) for the treatment of adult patients with chronic lymphocytic leukemia (CLL), the most common type of leukemia in adults.
Calquence showed promising clinical improvement in majority of 19 hospitalised COVID-19 patients worldpharmanews
June 08, 2020
Results published in Science Immunology showed that Calquence (acalabrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor, reduced markers of inflammation and improved clinical outcomes of patients with severe COVID-19 disease.(1)
AstraZeneca Initiates Calquence Clinical Trial against COVID-19 americanpharmaceuticalreview
April 16, 2020
AstraZeneca will initiate a randomized, global clinical trial to assess the potential of Calquence (acalabrutinib) in the treatment of the exaggerated immune response (cytokine storm) associated with COVID-19 infection in severely ill patients.
AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19 worldpharmanews
April 15, 2020
AstraZeneca will initiate a randomised, global clinical trial to assess the potential of Calquence (acalabrutinib) in the treatment of the exaggerated immune response (cytokine storm) associated with COVID-19 infection in severely ill patients.
AstraZeneca to trial Calquence to treat Covid-19 patients pharmaceutical-technology
April 15, 2020
AstraZeneca is set to conduct a global clinical trial of Calquence (acalabrutinib) to treat cytokine storm that manifests in severely ill Covid-19 patients.
CALQUENCE Granted US Breakthrough Therapy Designation americanpharmaceuticalreview
August 15, 2019
AstraZeneca announced the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for CALQUENCE® (acalabrutinib) as a monotherapy treatment for adult patients with chronic lymphocytic leukemia (CLL), one of the most common
AZ’ Calquence hits endpoints in late-stage leukemia trial pharmatimes
June 11, 2019
AstraZeneca has announced more positive results, this time from its Phase III ELEVATE-TN trial of Calquence (acalabrutinib) in patients with previously-untreated chronic lymphocytic leukaemia (CLL).
AstraZeneca's Calquence found success in lymphoma. Will CLL follow? fiercepharma
December 06, 2018
Just over a year after approval, AstraZenca’s Calquence is giving Johnson & Johnson and AbbVie’s Imbruvica a run for its money in mantle cell lymphoma.
FDA approves Calquence for adults with mantle cell lymphoma europeanpharmaceuticalreview
November 02, 2017
The FDA has granted accelerated approval to Calquence for the treatment of adults with mantle cell lymphoma…

Previous page 1 2 Next page